Clinical Trial: Phase IV Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat Growth Hormone Deficiency Children

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional

Official Title:

Brief Summary: This study evaluates the safety and efficiency of Pegylated Somatropin (PEG Somatropin) Injection in the treatment of endogenous growth hormone deficiency (GHD) in the broad population of children. Half of participants will receive the high dose, while the other half will receive the low dose.

Detailed Summary:
Sponsor: GeneScience Pharmaceuticals Co., Ltd.

Current Primary Outcome: Actual height of the patient after treatment compared with the mean height of the population and the standard deviation (SD) of the height of the population for that chronological age [ Time Frame: 26 weeks ]

Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: GeneScience Pharmaceuticals Co., Ltd.

Dates:
Date Received: November 27, 2014
Date Started: November 2014
Date Completion:
Last Updated: December 9, 2014
Last Verified: December 2014